Antibiotice S.A. Logo

Antibiotice S.A.

Develops and manufactures generic medicines and APIs, specializing in anti-infectives.

ATB | RO

Overview

Corporate Details

ISIN(s):
ROATBIACNOR9
LEI:
315700P5G4O1L6GLMS02
Country:
Romania
Address:
VALEA LUPULUI, 707410 IAȘI
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Antibiotice S.A. is a pharmaceutical company specializing in the development and manufacturing of generic medicines. With a history of over 65 years, the company produces a diverse portfolio of products for human use, including finished dosage forms and Active Pharmaceutical Ingredients (APIs). Its offerings have a strong focus on anti-infectives, such as penicillin-derived products. The company operates eight GMP-certified manufacturing lines and holds U.S. FDA approvals for key products, including Nystatin (API), Ampicillin for injection, and Nafcillin. Antibiotice is committed to making valuable medicines accessible and affordable for patients and healthcare professionals, driven by continuous investment in research, quality, and the modernization of its manufacturing technologies.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-07 07:37
Report Publication Announcement
Raport curent de informare a investitorilor
Romanian 546.9 KB
2025-11-06 12:52
Post-Annual General Meeting Information
Raport curent de informare a investitorilor
Romanian 643.5 KB
2025-11-06 12:49
Post-Annual General Meeting Information
Raport curent de informare a investitorilor
Romanian 1.0 MB
2025-11-05 10:20
Pre-Annual General Meeting Information
Raport curent de informare a investitorilor
Romanian 291.4 KB
2025-10-03 11:39
Pre-Annual General Meeting Information
Convocarea adunarii generale a actionarilor - RC11
Romanian 1.4 MB
2025-10-03 11:38
Pre-Annual General Meeting Information
Raport curent de informare a investitorilor
Romanian 1.7 MB
2025-10-01 12:53
Pre-Annual General Meeting Information
Raport curent de informare a investitorilor
Romanian 2.4 MB
2025-09-23 08:35
Pre-Annual General Meeting Information
Convocarea adunarii generale a actionarilor - RC11
Romanian 1.4 MB
2025-09-17 15:12
Post-Annual General Meeting Information
Raport curent de informare a investitorilor
Romanian 949.8 KB
2025-09-04 12:29
Notice of Dividend Amount
Plata dividend - RC17
Romanian 2.1 MB
2025-08-13 12:27
Pre-Annual General Meeting Information
Convocarea adunarii generale a actionarilor - RC11
Romanian 1.4 MB
2025-08-06 12:40
Report Publication Announcement
Raport curent de informare a investitorilor
Romanian 137.7 KB
2025-07-24 12:07
Pre-Annual General Meeting Information
Convocarea adunarii generale a actionarilor - RC11
Romanian 1.6 MB
2025-07-09 12:28
Board/Management Information
Raport curent de informare a investitorilor
Romanian 491.4 KB
2025-07-01 11:49
Post-Annual General Meeting Information
Raport curent de informare a investitorilor
Romanian 606.7 KB

Automate Your Workflow. Get a real-time feed of all Antibiotice S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Antibiotice S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Antibiotice S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
ChoA Pharmaceutical Co., LTD. Logo
Global manufacturer of OTC medicines and health supplements distributed through pharmacies.
South Korea 034940
CHUGAI PHARMACEUTICAL CO., LTD. Logo
An R&D pharma leader in Japan creating innovative drugs via antibody engineering technology.
Japan 4519
Cinclus Pharma Holding AB Logo
Clinical-stage pharma developing a next-gen P-CAB drug for severe GERD patients.
Sweden CINPHA
Cingulate Inc. Logo
Developing once-daily, precision timed-release drugs for ADHD and anxiety.
United States of America CING
Circio Holding ASA Logo
Developing circular RNA vector tech and immunotherapies for gene and cell therapies.
Norway CRNA
CITIUS ONCOLOGY, INC. Logo
Commercializing LYMPHIR™, an FDA-approved targeted therapy for cutaneous T-cell lymphoma.
United States of America CTOR
Citius Pharmaceuticals, Inc. Logo
Late-stage biopharma developing critical care products for oncology, infections, and stem cells.
United States of America CTXR
CJ Bioscience Logo
Develops microbiome therapeutics for oncology & IBD using an AI drug discovery platform.
South Korea 311690
CKD Bio Corp. Logo
Develops and manufactures probiotics & APIs using fermentation, also offering cGMP CMO services.
South Korea 063160
Clearmind Medicine Inc. Logo
Develops psychedelic-derived medicines for Alcohol Use Disorder and mental health conditions.
United States of America CMND

Talk to a Data Expert

Have a question? We'll get back to you promptly.